The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Disrupting tumour blood vessels
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)
Amano, M., Ito, M., Kimura, K., Fukata, Y., Chihara, K., Nakano, T., Matsuura, Y., & Kaibuchi, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20246 · Cited by 2,008
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593
Cytoskeletal regulation of pulmonary vascular permeability
Dudek, S. M., & Garcia, J. G. N. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.4.1487 · Cited by 985
Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
Gordon Steel, G., & Peckham, M. J. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 908
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 873
Transport of molecules across tumor vasculature
Jain, R. K. (1987) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00047468 · Cited by 866
Michel, C. C., & Curry, F. E. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.3.703 · Cited by 811
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
(1990) · PubMed · Cited by 757
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Dvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Self-citationVascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Garcia, J. G. N., Davis, H. W., & Patterson, C. E. (1995) · Journal of Cellular Physiology · doi:10.1002/jcp.1041630311 · Cited by 547
Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors
Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., & McDonald, D. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63540-7 · Cited by 528
Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions.
Less, J. R., Skalak, T. C., Sevick, E., & Jain, R. K. (1991) · PubMed · Cited by 501
Rho GTPases and the regulation of endothelial permeability
Wojciak-Stothard, B., & Ridley, A. J. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00008-9 · Cited by 470
Hendrix, M. J. C., Seftor, E. A., Meltzer, P. S., Gardner, L. M. G., Hess, A. R., Kirschmann, D. A., Schatteman, G. C., & Seftor, R. E. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131209798 · Cited by 456
Regulation of vascular permeability by vascular endothelial growth factors
Bates, D. O., & Harper, S. J. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00011-9 · Cited by 411
Dowlati, A., Robertson, K., Cooney, M. M., Petros, W. P., Stratford, M. R. L., Jesberger, J. A., Rafie, N., Overmoyer, B. A., Makkar, V., Stambler, B. S., et al. (2002) · PubMed · Cited by 403
Wachsberger, P. R., Burd, R., & Dicker, A. P. (2003) · PubMed · Cited by 395
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
Self-citationTozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
Self-citationDelivery of Molecular Medicine to Solid Tumors
Jain, R. K. (1996) · Science · doi:10.1126/science.271.5252.1079 · Cited by 312
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Role of Ca2+ signaling in the regulation of endothelial permeability
Tiruppathi, C., Minshall, R. D., Paria, B. C., Vogel, S. M., & Malik, A. B. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00007-7 · Cited by 306
Stevenson, J. P., Rosen, M., Sun, W., Gallagher, M., Haller, D. G., Vaughn, D., Giantonio, B., Zimmer, R., Petros, W. P., Stratford, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.986 · Cited by 291
Causes and Effects of Heterogeneous Perfusion in Tumors
Gillies, R. J., Schomack, P. A., Secomb, T. W., & Raghunand, N. (1999) · Neoplasia · doi:10.1038/sj.neo.7900037 · Cited by 283
Tozer, G. M., Prise, V. E., Wilson, J., Čemažar, M., Shan, S., Dewhirst, M. W., Barber, P. R., Vojnovic, B., & Chaplin, D. J. (2001) · PubMed · Cited by 283
Self-citationKanthou, C., & Tozer, G. M. (2002) · Blood · doi:10.1182/blood.v99.6.2060 · Cited by 280
Self-citationLin, C. M., Singh, S. B., Chu, P. S., Dempcy, R. O., Schmidt, J. M., Pettit, G. R., & Hamel, E. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09364-2 · Cited by 278
Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin, D. J., Pettit, G. R., & Hill, S. A. (1999) · PubMed · Cited by 252
Mechanisms of increased endothelial permeability
Lum, H., & Malik, A. B. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-74-7-787 · Cited by 251
Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate1a,
Pettit, G. R., Toki, B. E., Herald, D. L., Verdier‐Pinard, P., Boyd, M. R., Hamel, E., & Pettit, R. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970644q · Cited by 241
First steps of tumor-related angiogenesis.
Paku, S., & Paweletz, N. (1991) · PubMed · Cited by 238
Endothelial-cell proliferation in experimental tumours
Denekamp, J., & Hobson, B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.263 · Cited by 237
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis, P. D., Dougherty, G. J., Blakey, D. C., Galbraith, S. M., Tozer, G. M., Holder, A. L., Naylor, M. A., Nolan, J., Stratford, M. R. L., Chaplin, D. J., et al. (2002) · PubMed · Cited by 231
Self-citationTumor Blood Flow-Characterization, Modifications, and Role in Hyperthermia
Jain, R. K., & Ward-Hartley, K. (1984) · IEEE Transactions on Sonics and Ultrasonics · doi:10.1109/t-su.1984.31536 · Cited by 224
Konerding, M. A., Malkusch, W., Klapthor, B., Ackern, C. V., Fait, E., Hill, S. A., Parkins, C., Chaplin, D. J., Presta, M., & Denekamp, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690416 · Cited by 221
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.186 · Cited by 217
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., & Bibby, M. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6692174 · Cited by 213
Kasibhatla, S., Gourdeau, H., Meerovitch, K., Drewe, J., Reddy, S., Qiu, L., Zhang, H., Bergeron, F., Bouffard, D., Yang, Q., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1365.3.11 · Cited by 205
Dvorak, H. F., Nagy, J. A., & Dvořàk, A. M. (1991) · PubMed · Cited by 203
Dejana, E., Spagnuolo, R., & Bazzoni, G. (2001) · PubMed · Cited by 198
Corada, M., Zanetta, L., Orsenigo, F., Breviario, F., Lampugnani, M. G., Bernasconi, S., Liao, F., Hicklin, D. J., Bohlen, P., & Dejana, E. (2002) · Blood · doi:10.1182/blood.v100.3.905 · Cited by 195
Combretastatin A4 phosphate: background and current clinical status
Young, S. L., & Chaplin, D. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1171 · Cited by 192
Antivascular therapy of cancer: DMXAA
Baguley, B. C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01018-0 · Cited by 187
Self-citationAntitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey, D. C., Westwood, F. R., Walker, M., et al. (2002) · PubMed · Cited by 176
Sevick, E., & Jain, R. K. (1989) · PubMed · Cited by 175
Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation
Verin, A. D., Birukova, A., Wang, P., Liu, F., Becker, P., Birukov, K., & Garcia, J. G. N. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.3.l565 · Cited by 174
Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., & Jonathan Zwi, L. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90391-p · Cited by 172
Self-citationVinca alkaloids: Anti-vascular effects in a murine tumour
Hill, S. A., Lonergan, S. J., Denekamp, J., & Chaplin, D. J. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90082-q · Cited by 168
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
Siemann, D. W., Mercer, E., Lepler, S., & Rojiani, A. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10316 · Cited by 166
Galbraith, S. M., Chaplin, D. J., Lee, F., Stratford, M. R. L., Locke, R. J., Vojnovic, B., & Tozer, G. M. (2001) · PubMed · Cited by 165
Self-citationVaupel, P. W., & Höckel, M. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.5.869 · Cited by 165
Spagnuolo, R., Bazzoni, G., & Dejana, E. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616228 · Cited by 164
Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy
TOZER, G. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.015 · Cited by 163
Self-citationParia, B. C., Vogel, S. M., Ahmmed, G. U., Alamgir, S., Shroff, J., Malik, A. B., & Tiruppathì, C. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00240.2004 · Cited by 157
Iyer, S., Chaplin, D. J., Rosenthal, D. S., et al. (1998) · PubMed · Cited by 147
Galbraith, S. M., Rustin, G. J. S., Lodge, M. A., Taylor, N. J., Stirling, J., Jameson, M. B., Thompson, P. I., Hough, D., Gumbrell, L. A., & Padhani, A. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.144 · Cited by 144
Vascular occlusion and tumour cell death
Denekamp, J., Hill, S. A., & Hobson, B. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90426-1 · Cited by 140
Milosevic, M., Fyles, A., & Hill, R. P. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00512-4 · Cited by 139
Korbelik, M., & Cecić, I. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00349-8 · Cited by 139
Plowman, J., Narayanan, V. L., Dykes, D. J., Szarvasi, E., Briet, P., Yoder, O. C., & Paull, K. D. (1986) · PubMed · Cited by 137
Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J. T., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L. A., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600992 · Cited by 136
Self-citationCooney, M. M., Radivoyevitch, T., Dowlati, A., Overmoyer, B. A., Levitan, N. I., Robertson, K., Levine, S. L., DeCaro, K., Buchter, C. M., Taylor, A. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0364-3 · Cited by 135
Kanthou, C., Greco, O., Stratford, A. L., Cook, I. O., Knight, R. A., Benzakour, O., & Tozer, G. M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63398-6 · Cited by 130
Self-citationIntracapillary oxyhemoglobin saturation of malignant tumors in humans
Mueller‐Klieser, W., Vaupel, P. W., Manz, R., & Schmidseder, R. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90036-5 · Cited by 130
Li, L., Rojiani, A. M., & Siemann, D. W. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00320-4 · Cited by 130
Hori, K., & Saito, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601261 · Cited by 123
Ching, L., Cao, Z., Kiéda, C., Zwain, S., Jameson, M. B., & Bc, B. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600368 · Cited by 123
Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E., & Neeman, M. (1999) · PubMed · Cited by 121
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
Murata, R., Siemann, D. W., Overgaard, J., & Horsman, M. R. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00384-x · Cited by 109
Pedley, R. B., Hill, S. A., Boxer, G., Flynn, A. A., Boden, R. W., Watson, R., Dearling, J. L. J., Chaplin, D. J., & Beǵent, R. H. J. (2001) · PubMed · Cited by 108
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
Theys, J., Landuyt, W., Nuyts, S., Mellaert, L. V., van Oosterom, A., Lambin, P., & Anné, J. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700303 · Cited by 106
Rustin, G. J. S., Bradley, C., Galbraith, S. M., Stratford, M. R. L., Loadman, P. M., Waller, S., Bellenger, K., Gumbrell, L. A., Folkes, L. K., & Halbert, G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600885 · Cited by 105
Effect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87 Glioblastoma
Wachsberger, P. R., Burd, R., Marero, N., Daskalakis, C., Ryan, A. J., McCue, P. A., & Dicker, A. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.835.11.2 · Cited by 105
Lash, C., Li, A. E., Rutland, M. D., Baguley, B., Zwi, L. J., & Wilson, W. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.512 · Cited by 99
Self-citationBeauregard, D. A., Thelwall, P., Chaplin, D. J., Hill, S., Adams, G., & Brindle, K. M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.294 · Cited by 99
Wilson, W. R., Li, A., Cowan, D. M., & Siim, B. G. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00358-7 · Cited by 97
Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action
Hill, S. A., Williams, K. B., & Denekamp, J. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90099-0 · Cited by 96
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours
Smith, G. P., Calveley, S. B., Smith, M. J., & Baguley, B. C. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90157-x · Cited by 95
Self-citationTozer, G., Lewis, S., Michałowski, A., & Aber, V. R. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.46 · Cited by 89
Self-citationSheng, Y., Hua, J., Pinney, K. G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20297 · Cited by 88
Ching, L.-M., Goldsmith, D., Joseph, W. R., Körner, H., Sedgwick, J. D., & Bc, B. (1999) · PubMed · Cited by 87
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
Siemann, D. W., & Shi, W. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.002 · Cited by 87
McGown, A., & Fox, B. (1989) · PubMed · Cited by 83
Prise, V. E., Honess, D. J., Stratford, M. R. L., Wilson, J., & Tozer, G. M. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.4.717 · Cited by 82
Self-citationGrosios, K., Loadman, P. M., Swaine, D. J., et al. (2000) · PubMed · Cited by 81
Murata, R., Siemann, D. W., Overgaard, J., & Horsman, M. R. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)156[0503:itrbcr]2.0.co;2 · Cited by 80
TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death
Otani, M., Natsume, T., Watanabe, J., Kobayashi, M., Murakoshi, M., Mikami, T., & Nakayama, T. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01022.x · Cited by 76
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents.
Zwi, L. J., Bc, B., Gavin, J. B., & Wilson, W. R. (1994) · PubMed · Cited by 76
Hori, K., Saito, S., & Kubota, K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600296 · Cited by 75
Zhao, L., Ching, L., Kestell, P., Kèlland, L. R., & Baguley, B. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21005 · Cited by 71
Self-citationHypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton
Park, J. H., Okayama, N., Gute, D. C., Krsmanovic, A., Battarbee, H. D., & Alexander, J. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.6.c1066 · Cited by 71
Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503
Hill, S. A., Toze, G. M., Pettit, G. R., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80764-x · Cited by 66
Hua, J., Sheng, Y., Pinney, K. G., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80778-x · Cited by 66
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
Nihei, Y., Suzuki, M., Okano, A., Tsuji, T., Akiyama, Y., Tsuruo, T., Saito, S., Hori, K., & Sato, Y. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00724.x · Cited by 66
R. Murata, J. O. (2001) · International Journal of Radiation Biology · doi:10.1080/09553000010007695 · Cited by 65
Bc, B., Li, Z., & Kestell, P. (1997) · PubMed · Cited by 65
Nihei, Y., Suga, Y., Morinaga, Y., Ohishi, K., Okano, A., Ohsumi, K., Hatanaka, T., Nakagawa, R., Tsuji, T., Akiyama, Y., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00850.x · Cited by 58
Kallinowski, F., Schaefer, C. A., Tyler, G., & Vaupel, P. W. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.312 · Cited by 57
Cao, Z., Bc, B., & Ching, L. (2001) · PubMed · Cited by 53
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
Parkins, C. S., Holder, A. L., Hill, S. A., Chaplin, D. J., & Tozer, G. M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1361 · Cited by 51
Self-citationNitro reduction as an electronic switch for bioreductive drug activation.
Siim, B. G., Denny, W. A., & Wilson, W. R. (1997) · PubMed · Cited by 50
Recent advances in the field of tubulin polymerization inhibitors
Prinz, H. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.6.695 · Cited by 48
Segreti, J. A., Polakowski, J. S., Koch, K., Marsh, K. C., Bauch, J. L., Rosenberg, S. H., Sham, H., Cox, B. F., & Reinhart, G. A. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0807-0 · Cited by 45
Ahmed, B., van Eijk, L. I., Steege, J. C. A. B.-T., van der Schaft, D. W. J., van Esch, A. M., Joosten-Achjanie, S., Lambin, P., Landuyt, W., & Griffioen, A. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11010 · Cited by 45
Targeting the tumor vasculature: a strategy to improve radiation therapy
Siemann, D. W., & Horsman, M. R. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.2.321 · Cited by 33
Red Blood Cell Behavior at Low Flow Rate in Microvessels
Lominadze, D. G., & Mchedlishvili, G. I. (1999) · Microvascular Research · doi:10.1006/mvre.1999.2160 · Cited by 30
Ye, L.-H., Kishi, H., Nakamura, A., Okagaki, T., Tanaka, T., Oiwa, K., & Kohama, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6666 · Cited by 24
Alexander, J., Hechtman, H. B., & Sheṕro, D. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90643-7 · Cited by 21
Wang, L. S., Reddy, C. B., Baguley, B. C., Kestell, P., Sutherland, R., & Ching, L. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.10.023 · Cited by 21
Self-citation
Cited by
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Photodynamic therapy of cancer. Basic principles and applications
Juarranz, Á., Jaén, P., Sanz-Rodríguez, F., Cuevas, J., & González, S. (2008) · Clinical and Translational Oncology · doi:10.1007/s12094-008-0172-2 · Cited by 762
Medicinal Chemistry of Combretastatin A4: Present and Future Directions
Tron, G. C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., & Genazzani, A. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512903 · Cited by 629
Metadata
- Authors
- Tozer, G. M., Kanthou, C., & Baguley, B. C.
- Venue
- Nature Reviews Cancer
- Published
- 2005-06
- Volume
- 5
- Issue
- 6
- Pages
- 423-435
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1966726954
- Cited by
- 930
- References
- 114
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.